BMS’ Opdivo (nivolumab) Receives EC’s Approval as 2L Treatment for Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma

November 25, 2020 Auto Bot Bristol-Myers Squibb, Nivolumab, Opdivo, receives, regulatory 0

Shots:

  • The approval is based on P-lll ATTRACTION-3 study involve the assessment of Opdivo vs CT (docetaxel or paclitaxel) for patients with esophageal cancer refractory/ intolerant to 1L combination therapy with fluoropyrimidine- and Pt.-based drugs
  • Results: reduction in risk of death (23%); m-OS (10.9 vs 8.4 mos.); @12 & 18-mos. OS rates (47% & 31% vs 34% & 21%); ORR (19% and 22%); DoR (6.9 vs 3.9 mos.)
  • Opdivo is a PD-1 immune checkpoint inhibitor, designed to harness the body’s immune system to help restore anti-tumor immune response and is the first immunotherapy to be approved for gastroesophageal cancer in the EU

Click here ­to­ read full press release/ article | Ref: Bristol Myers Squibb | Image: Bristol Myers Squibb

The post BMS’ Opdivo (nivolumab) Receives EC’s Approval as 2L Treatment for Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma first appeared on PharmaShots.